E
10x Genomics, Inc.
TXG
$11.70
$0.232.01%
E
Sell
3/14/2023Downgrade
10x Genomics, Inc. (TXG) was downgraded to E+ from D on 3/14/2023 due to a noticeable decline in the growth index.
10x Genomics, Inc. (TXG) was downgraded to E+ from D on 3/14/2023 due to a noticeable decline in the growth index.
D
Sell
2/9/2023Upgraded
10x Genomics, Inc. (TXG) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
10x Genomics, Inc. (TXG) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
10x Genomics, Inc. (TXG) was downgraded to E+ from D on 2/8/2023 due to a decline in the valuation index.
10x Genomics, Inc. (TXG) was downgraded to E+ from D on 2/8/2023 due to a decline in the valuation index.
D
Sell
12/6/2022Upgraded
10x Genomics, Inc. (TXG) was upgraded to D from D- on 12/6/2022 due to an increase in the total return index and valuation index.
10x Genomics, Inc. (TXG) was upgraded to D from D- on 12/6/2022 due to an increase in the total return index and valuation index.
D
Sell
11/21/2022Downgrade
10x Genomics, Inc. (TXG) was downgraded to D- from D on 11/21/2022 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 4.88 to 4.22.
10x Genomics, Inc. (TXG) was downgraded to D- from D on 11/21/2022 due to a decline in the total return index, solvency index and volatility index. The quick ratio declined from 4.88 to 4.22.
D
Sell
8/10/2022Upgraded
10x Genomics, Inc. (TXG) was upgraded to D from D- on 8/10/2022 due to a noticeable increase in the growth index and valuation index. Operating cash flow increased 18.45% from -$20.8M to -$16.96M, and total revenue increased 0.1% from $114.5M to $114.61M.
10x Genomics, Inc. (TXG) was upgraded to D from D- on 8/10/2022 due to a noticeable increase in the growth index and valuation index. Operating cash flow increased 18.45% from -$20.8M to -$16.96M, and total revenue increased 0.1% from $114.5M to $114.61M.
D
Sell
6/3/2022Downgrade
10x Genomics, Inc. (TXG) was downgraded to D- from D on 6/3/2022 due to a decline in the total return index and volatility index.
10x Genomics, Inc. (TXG) was downgraded to D- from D on 6/3/2022 due to a decline in the total return index and volatility index.
D
Sell
5/16/2022Upgraded
10x Genomics, Inc. (TXG) was upgraded to D from E+ on 05/16/2022.
10x Genomics, Inc. (TXG) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
10x Genomics, Inc. (TXG) was downgraded to E+ from D on 5/13/2022 due to a significant decline in the growth index, total return index and solvency index. EBIT declined 3,593.36% from -$1.13M to -$41.74M, operating cash flow declined 458.35% from $5.81M to -$20.8M, and earnings per share declined from -$0.1672 to -$0.3754.
10x Genomics, Inc. (TXG) was downgraded to E+ from D on 5/13/2022 due to a significant decline in the growth index, total return index and solvency index. EBIT declined 3,593.36% from -$1.13M to -$41.74M, operating cash flow declined 458.35% from $5.81M to -$20.8M, and earnings per share declined from -$0.1672 to -$0.3754.
D
Sell
5/4/2022Upgraded
10x Genomics, Inc. (TXG) was upgraded to D from E+ on 05/04/2022.
10x Genomics, Inc. (TXG) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
10x Genomics, Inc. (TXG) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
10x Genomics, Inc. (TXG) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
D
Sell
4/21/2022Upgraded
10x Genomics, Inc. (TXG) was upgraded to D from E+ on 04/21/2022.
10x Genomics, Inc. (TXG) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
10x Genomics, Inc. (TXG) was downgraded to E+ from D on 4/20/2022 due to a noticeable decline in the volatility index, total return index and valuation index.
10x Genomics, Inc. (TXG) was downgraded to E+ from D on 4/20/2022 due to a noticeable decline in the volatility index, total return index and valuation index.
D
Sell
12/21/2021Downgrade
10x Genomics, Inc. (TXG) was downgraded to D from D+ on 12/21/2021 due to a decline in the volatility index and total return index.
10x Genomics, Inc. (TXG) was downgraded to D from D+ on 12/21/2021 due to a decline in the volatility index and total return index.
D
Sell
12/6/2021Upgraded
10x Genomics, Inc. (TXG) was upgraded to D+ from D on 12/6/2021 due to an increase in the volatility index and valuation index.
10x Genomics, Inc. (TXG) was upgraded to D+ from D on 12/6/2021 due to an increase in the volatility index and valuation index.
D
Sell
11/23/2021Upgraded
10x Genomics, Inc. (TXG) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
10x Genomics, Inc. (TXG) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
D
Sell
11/8/2021Downgrade
10x Genomics, Inc. (TXG) was downgraded to D- from D+ on 11/8/2021 due to a noticeable decline in the growth index, total return index and solvency index. Operating cash flow declined 940.26% from $3.12M to -$26.22M, and earnings per share declined from -$0.1006 to -$0.1549.
10x Genomics, Inc. (TXG) was downgraded to D- from D+ on 11/8/2021 due to a noticeable decline in the growth index, total return index and solvency index. Operating cash flow declined 940.26% from $3.12M to -$26.22M, and earnings per share declined from -$0.1006 to -$0.1549.
D
Sell
1/29/2021Upgraded
10x Genomics, Inc. (TXG) was upgraded to D+ from D on 1/29/2021 due to a large increase in the total return index and solvency index. The quick ratio increased from 2.97 to 5.53.
10x Genomics, Inc. (TXG) was upgraded to D+ from D on 1/29/2021 due to a large increase in the total return index and solvency index. The quick ratio increased from 2.97 to 5.53.
D
Sell
2/28/2020Downgrade
10x Genomics, Inc. (TXG) was downgraded to D from C- on 2/28/2020 due to a substantial decline in the growth index, efficiency index and volatility index. Operating cash flow declined 53.88% from $14.53M to $6.7M, and total capital declined 0.3% from $451.14M to $449.8M.
10x Genomics, Inc. (TXG) was downgraded to D from C- on 2/28/2020 due to a substantial decline in the growth index, efficiency index and volatility index. Operating cash flow declined 53.88% from $14.53M to $6.7M, and total capital declined 0.3% from $451.14M to $449.8M.
C
Hold
12/12/2019Upgraded
10x Genomics, Inc. (TXG) was upgraded to C- from D+ on 12/12/2019 due to a large increase in the total return index.
10x Genomics, Inc. (TXG) was upgraded to C- from D+ on 12/12/2019 due to a large increase in the total return index.
D
Sell
12/5/2019None
10x Genomics, Inc. (TXG) was downgraded to D+ from U on 12/05/2019.
10x Genomics, Inc. (TXG) was downgraded to D+ from U on 12/05/2019.
NASDAQ
03/07/2025 3:00PM Eastern
Quotes delayed
